Moscow Oncology Hospital 62, Istra PIC, 27, 143423 Moscow, Russian Federation; Department of Molecular Biology, Moscow Oncology Hospital 62, Istra PIC, 27, 143423, Moscow, Russian Federation.
Moscow Oncology Hospital 62, Istra PIC, 27, 143423 Moscow, Russian Federation; Department of Pathology, Moscow Oncology Hospital 62, Istra PIC, 27, 143423, Moscow, Russian Federation.
Lung Cancer. 2017 Jan;103:17-23. doi: 10.1016/j.lungcan.2016.11.001. Epub 2016 Nov 13.
Clinical guidelines highly recommended the detection of potentially targetable genetic aberrations such as anaplastic lymphoma kinase (ALK) rearrangements in patients with non-small cell lung cancer (NSCLC). Few methods, such as the ALK break apart FISH assay and IHC for ALK protein, are approved for routine diagnostics. However, some challenges exist in selecting the most reliable, robust and cost-effective algorithm, especially for large-scale screening of NSCLC patients.
A total of 4002 FFPE samples from Russian patients with NSCLC were tested for ALK rearrangement using two algorithms: FISH testing only (2334 samples) and IHC screening supported by FISH in positive or equivocal cases (1546 samples). Cross validation of the methods was performed blindly in 122 specimens. All discrepant IHC/FISH cases were examined for unbalanced 5'/3'-end ALK expression and variant-specific RT PCR.
The sensitivity and specificity of IHC compared to FISH was 100% and 99%, respectively, therefore initial IHC screening was strongly supported. The prevalence of ALK rearrangements was estimated to be 7.8% and 6.6% for the FISH and IHC/FISH groups, respectively, with significant correlations for female gender, non-smoking status and age below 60. The use of FISH after IHC screening revealed 10 additional positive cases among equivocal samples (13.4%). Seven IHC/FISH cases (0.5% of the total group) characterized as discordant were reevaluated, and four were reclassified as truly discrepant. The PCR-based investigation revealed chimeric transcripts in IHC-/FISH+ and IHC+/FISH borderline samples, while no transcript was found in two IHC+/FISH- cases.
These results reveal the utility of the two-step testing algorithm for the evaluation of potentially complicated cases with preanalytic defects, providing additional information for IHC equivocal cases without a significant increase in cost. The evaluation of discrepant cases appears to be necessary to better understand ALK biology and should be included in the routine testing algorithm.
临床指南强烈建议检测非小细胞肺癌(NSCLC)患者中潜在的可靶向遗传异常,如间变性淋巴瘤激酶(ALK)重排。虽然有一些方法,如 ALK 分离 FISH 检测和 ALK 蛋白免疫组化(IHC),已被批准用于常规诊断,但在选择最可靠、最稳健和最具成本效益的算法方面仍存在一些挑战,特别是在对大量 NSCLC 患者进行筛查时。
对来自俄罗斯 NSCLC 患者的 4002 例 FFPE 样本使用两种算法进行 ALK 重排检测:仅进行 FISH 检测(2334 例)和在阳性或不确定病例中进行 IHC 筛选并支持 FISH(1546 例)。在 122 个样本中进行了方法的盲法交叉验证。对所有不一致的 IHC/FISH 病例进行了 5'/3'-端 ALK 表达不平衡和变体特异性 RT-PCR 检查。
与 FISH 相比,IHC 的灵敏度和特异性分别为 100%和 99%,因此强烈支持初始 IHC 筛选。ALK 重排的患病率估计为 FISH 组的 7.8%和 IHC/FISH 组的 6.6%,女性、不吸烟和年龄<60 与 FISH 和 IHC/FISH 组均有显著相关性。在 IHC 筛选后使用 FISH 检测在不确定样本中发现了 10 例额外的阳性病例(占不确定样本的 13.4%)。对 7 例 IHC/FISH 病例(总组的 0.5%)进行了重新评估,其中 4 例被重新归类为真正不一致。基于 PCR 的研究显示,在 IHC-/FISH+和 IHC+/FISH 边界样本中存在嵌合转录本,而在 2 例 IHC+/FISH-病例中未发现转录本。
这些结果表明,两步检测算法可用于评估具有分析前缺陷的潜在复杂病例,为 IHC 不确定病例提供额外信息,而不会显著增加成本。评估不一致的病例似乎是必要的,以便更好地了解 ALK 生物学,并且应该包含在常规检测算法中。